• Rhea Regi

Title: NTproBNP, A Novel Cardiac Biomarker as a Prognostic Indicator in Acute Coronary Syndromes Author: Dr. Rhea Regi Introduction: Cardiovascular diseases account for 32% of global deaths, with Acute Coronary Syndrome (ACS) being a leading cause. Despite treatment, ACS patients remain at high risk for future cardiac events. NTproBNP, an inactive remnant of BNP released from cardiac myocytes, has a longer half-life and is used as a prognostic marker for ACS. Aim & Objectives: Assess NTproBNP as a prognostic indicator in ACS. Determine if NTproBNP levels correlate with recurrent angina, hospital admissions, mortality, and left ventricular (LV) dysfunction. Methods: Study Design: Prospective observational study. Period: September 2022 - July 2023. Population: 54 ACS patients (unstable angina, NSTEMI, STEMI) at Dr balasaheb vikhe patil rural medical college,loni Inclusion Criteria: Patients <65 years with no prior cardiac history, presenting within 24 hours of ACS symptoms. Exclusion Criteria: Age >65, anemia, sepsis, renal failure. Follow-up: 6 months, monitoring symptoms, LV function via 2D ECHO, and hospital admissions. Results: NTproBNP was elevated in 40 out of 54 patients (74%). NTproBNP levels and ACS Type: More commonly elevated in STEMI (80.5%) than NSTEMI (75%) or unstable angina (57.2%). Correlation of NTproBNP elevation with outcomes: Recurrent Angina: 90.3% of patients with NTproBNP >100 pg/ml had recurrent angina (p=0.001). LV Dysfunction: 60% of patients with NTproBNP >100 pg/ml developed LV dysfunction (p=0.005). Hospital Admissions: 52.5% of patients with NTproBNP >100 pg/ml required hospitalization (p=0.009). Mortality: 9 deaths, all in patients with NTproBNP >100 pg/ml (p=0.021). Discussion & Conclusion: NTproBNP is significantly elevated in ACS, particularly in STEMI. High NTproBNP levels predict recurrent angina, LV dysfunction, hospital admissions, and mortality. It is a reliable prognostic biomarker for ACS and should be used for closer monitoring of high-risk patients. Limitations: Small sample size. Geriatric patients excluded, though they are at higher risk. Fewer female participants due to exclusion of patients >65 years, as women typically develop ACS later in life.

"NTproBNP, a novel cardiac biomarker as a prognostic indicator in acute coronary syndrome", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.12, Issue 2, page no.b712-b715, February-2025, Available :http://www.jetir.org/papers/JETIR2502171.pdf

"NTproBNP, a novel cardiac biomarker as a prognostic indicator in acute coronary syndrome", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.12, Issue 2, page no. ppb712-b715, February-2025, Available at : http://www.jetir.org/papers/JETIR2502171.pdf